YK-029A is an orally active inhibitor of mutant EGFR,targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity,and results tumor regression in EGFRex20ins-driven PDX models[1].
Molecular Weight:
500.60
Purity:
99.50
CAS Number:
[2064269-82-3]
Formula:
C27H32N8O2
Target:
EGFR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
